|
WO2003093261A1
(en)
|
2002-04-30 |
2003-11-13 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
KR101146806B1
(ko)
*
|
2003-03-12 |
2012-05-22 |
메이브릿지 리미티드 |
프탈라지논 유도체
|
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
GB0317466D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
US7456180B2
(en)
|
2003-07-30 |
2008-11-25 |
Xenon Pharmaceuticals Inc. |
Piperazine derivatives and their use as therapeutic agents
|
|
SG145745A1
(en)
|
2003-08-06 |
2008-09-29 |
Senomyx Inc |
Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
RU2413515C2
(ru)
*
|
2003-12-01 |
2011-03-10 |
Кудос Фармасьютикалс Лимитед |
Ингибиторы репарации повреждения днк для лечения рака
|
|
GB0419072D0
(en)
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
BRPI0514632A
(pt)
*
|
2004-08-26 |
2008-06-17 |
Kudos Pharm Ltd |
derivados de ftalazinona 4-heteroarilmetila substituìdos
|
|
EP1645556A1
(en)
*
|
2004-10-07 |
2006-04-12 |
Boehringer Ingelheim International GmbH |
Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
|
|
EP1850681B1
(en)
|
2005-02-04 |
2019-12-18 |
Firmenich Incorporated |
Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
AR055329A1
(es)
|
2005-06-15 |
2007-08-15 |
Senomyx Inc |
Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
|
|
WO2007035010A2
(en)
|
2005-09-23 |
2007-03-29 |
Equispharm Co., Ltd |
5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
|
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
|
KR101387563B1
(ko)
|
2006-04-21 |
2014-04-25 |
세노믹스, 인코포레이티드 |
고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
|
|
GB0610680D0
(en)
|
2006-05-31 |
2006-07-12 |
Istituto Di Ricerche D Biolog |
Therapeutic compounds
|
|
US7834015B2
(en)
|
2006-05-31 |
2010-11-16 |
Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
|
|
JP2009539962A
(ja)
*
|
2006-06-15 |
2009-11-19 |
クドス ファーマシューティカルズ リミテッド |
Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
|
|
WO2008020180A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Kudos Pharmaceuticals Limited |
Methods of increasing the sensitivity of cancer cells to dna damage
|
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
AU2013201880B2
(en)
*
|
2006-10-17 |
2015-06-25 |
Kudos Pharmaceuticals Limited |
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
PE20081229A1
(es)
*
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
PT2698062E
(pt)
*
|
2006-12-28 |
2015-10-19 |
Abbvie Inc |
Inibidores da poli (adp-ribose) polimerase
|
|
AU2008256562A1
(en)
*
|
2007-05-25 |
2008-12-04 |
Astrazeneca Ab |
Combination of CHK and PARP inhibitors for the treatment of cancers
|
|
CA2687931C
(en)
|
2007-05-31 |
2016-05-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists and uses thereof
|
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
|
GB0716532D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
CN102083314B
(zh)
*
|
2007-10-03 |
2014-04-30 |
卫材股份有限公司 |
Parp抑制剂化合物、组合物以及使用方法
|
|
JP5593229B2
(ja)
*
|
2007-10-17 |
2014-09-17 |
クドス ファーマシューティカルズ リミテッド |
４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン
|
|
EP2220073B1
(en)
*
|
2007-11-15 |
2014-09-03 |
MSD Italia S.r.l. |
Pyridazinone derivatives as parp inhibitors
|
|
CL2008003553A1
(es)
*
|
2007-12-05 |
2009-11-27 |
Grindeks Jsc |
Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
|
|
AU2008335135A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Cytopathfinder, Inc. |
Carboxamide compounds and their use as chemokine receptor agonists
|
|
AR070221A1
(es)
*
|
2008-01-23 |
2010-03-25 |
Astrazeneca Ab |
Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
|
|
DK2767537T3
(da)
|
2008-08-06 |
2017-06-19 |
Medivation Technologies Inc |
Dihydropyridophthalazinon-hæmmere af poly(adp-ribose)polymerase (parp)
|
|
UA106878C2
(uk)
|
2008-10-07 |
2014-10-27 |
Астразенека Юк Лімітед |
Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
|
|
EP2379525B1
(en)
|
2008-12-19 |
2015-07-29 |
Boehringer Ingelheim International GmbH |
Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
|
|
UY32790A
(es)
*
|
2009-07-15 |
2011-02-28 |
Astrazeneca Ab |
Compuesto de ftalazinona
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
|
EP2322658A1
(en)
|
2009-11-13 |
2011-05-18 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of breast cancer aggressiveness and genetic instability
|
|
PH12012501215A1
(en)
|
2009-12-17 |
2015-11-13 |
Centrexion Therapeutics Corp |
New ccr2 receptor antagonists and uses thereof
|
|
CN106943406A
(zh)
*
|
2010-02-03 |
2017-07-14 |
麦迪韦逊科技有限公司 |
用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
|
|
ES2606174T3
(es)
|
2010-02-08 |
2017-03-23 |
Medivation Technologies, Inc. |
Procesos de síntesis de derivados de dihidropiridoftalazinona
|
|
WO2011141477A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
EP2569298B1
(en)
|
2010-05-12 |
2015-11-25 |
Boehringer Ingelheim International GmbH |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
US8841313B2
(en)
|
2010-05-17 |
2014-09-23 |
Boehringer Ingelheim International Gmbh |
CCR2 antagonists and uses thereof
|
|
US9018212B2
(en)
|
2010-05-25 |
2015-04-28 |
Boehringer Ingelheim International Gmbh |
Pyridazine carboxamides as CCR2 receptor antagonists
|
|
JP5721242B2
(ja)
|
2010-06-01 |
2015-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ｃｃｒ２アンタゴニスト
|
|
JP2013532683A
(ja)
*
|
2010-07-27 |
2013-08-19 |
カディラ ヘルスケア リミティド |
ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
|
|
CN102372716A
(zh)
*
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
SG189939A1
(en)
*
|
2010-10-21 |
2013-06-28 |
Biomarin Pharm Inc |
Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
|
|
ES2590682T3
(es)
*
|
2010-12-02 |
2016-11-23 |
Shanghai De Novo Pharmatech Co Ltd. |
Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
|
|
CA2829123C
(en)
*
|
2011-03-14 |
2016-04-12 |
Eternity Bioscience Inc. |
Quinazolinediones and their use
|
|
CA2833914A1
(en)
*
|
2011-05-10 |
2012-11-15 |
Universite Laval |
Methods for the treatment and diagnostic of pulmonary arterial hypertension
|
|
EP2710142B1
(en)
|
2011-05-18 |
2017-04-26 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of cancer aggressiveness and genetic instability
|
|
JP5960253B2
(ja)
*
|
2011-05-31 |
2016-08-02 |
ニューゲン セラピューティクス， インコーポレイテッド |
ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
|
|
EP2731941B1
(en)
|
2011-07-15 |
2019-05-08 |
Boehringer Ingelheim International GmbH |
Novel and selective ccr2 antagonists
|
|
ES2937269T3
(es)
|
2011-07-22 |
2023-03-27 |
Pacylex Pharmaceuticals Inc |
Letalidad sintética y el tratamiento del cáncer
|
|
CN103130723B
(zh)
*
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN104145030B
(zh)
|
2012-01-05 |
2016-10-12 |
国家科学研究中心 |
用于诊断肺癌侵袭性和遗传不稳定性的标记
|
|
CN102964354B
(zh)
*
|
2012-11-16 |
2014-08-13 |
江苏先声药业有限公司 |
一类噻吩并咪唑衍生物及其应用
|
|
MX2015006780A
(es)
|
2012-12-31 |
2015-08-06 |
Cadila Healthcare Ltd |
Derivados de ftalazin-1-(2h)-ona sustituida.
|
|
US9790215B2
(en)
|
2013-03-13 |
2017-10-17 |
Flatley Discovery Lab, Llc |
Pyridazinone compounds and methods for the treatment of cystic fibrosis
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
EP2970121B1
(en)
*
|
2013-03-15 |
2017-12-13 |
Araxes Pharma LLC |
Covalent inhibitors of kras g12c
|
|
CA2919905C
(en)
*
|
2013-07-31 |
2021-08-10 |
Merck Patent Gmbh |
Oxoquinazolinyl-butanamide derivatives
|
|
LT3030554T
(lt)
*
|
2013-08-07 |
2018-05-10 |
Merck Patent Gmbh |
Piperidin-karbamido dariniai
|
|
KR101670126B1
(ko)
*
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
CN105985294B
(zh)
*
|
2015-02-11 |
2020-12-25 |
四川科伦药物研究院有限公司 |
一种奥拉帕尼的制备方法
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
CN106146492A
(zh)
*
|
2015-04-17 |
2016-11-23 |
上海汇伦生命科技有限公司 |
杂环并咪唑类化合物、其药物组合物及其制备方法和用途
|
|
MX2017014163A
(es)
*
|
2015-05-06 |
2018-08-15 |
Univ California |
Moduladores de k-ras.
|
|
WO2016187620A2
(en)
|
2015-05-21 |
2016-11-24 |
The Regents Of The University Of California |
Anti-cancer compounds
|
|
MX383744B
(es)
|
2015-07-02 |
2025-03-14 |
Centrexion Therapeutics Corp |
Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
|
|
EP3325662B1
(en)
|
2015-07-17 |
2023-08-30 |
Pacylex Pharmaceuticals Inc. |
Epigenetic silencing of nmt2
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
AU2016296905B2
(en)
|
2015-07-23 |
2018-07-05 |
Centre National De La Recherche Scientifique |
Use of a combination of Dbait molecule and parp inhibitors to treat cancer
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
CN106554316B
(zh)
*
|
2015-09-28 |
2019-03-08 |
上海医药集团股份有限公司 |
一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
KR20240113606A
(ko)
|
2015-11-16 |
2024-07-22 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US10857156B2
(en)
|
2015-11-20 |
2020-12-08 |
Senhwa Biosciences, Inc. |
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
|
CZ201682A3
(cs)
|
2016-02-15 |
2017-08-23 |
Zentiva, K.S. |
Solvatované krystalické formy olaparibu, jejich příprava a použití
|
|
WO2017191562A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Alembic Pharmaceuticals Limited |
Process for the preparation of olaparib and polymorphs thereof
|
|
AU2017280334C1
(en)
|
2016-06-24 |
2022-10-20 |
AtlasMedx, Inc |
Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer
|
|
CZ2016391A3
(cs)
|
2016-06-29 |
2018-01-10 |
Zentiva, K.S. |
Farmaceutická formulace olaparibu
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CN109563080B
(zh)
*
|
2016-08-24 |
2021-07-30 |
台湾神隆股份有限公司 |
奥拉帕尼的制备方法
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
CN107955001A
(zh)
*
|
2016-10-14 |
2018-04-24 |
上海汇伦生命科技有限公司 |
抗肿瘤杂环并咪唑类化合物的药用盐
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
JP2020517600A
(ja)
|
2017-04-20 |
2020-06-18 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｋ−Ｒａｓモジュレーター
|
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
CA3031777A1
(en)
|
2018-01-31 |
2019-07-31 |
Apotex Inc. |
Crystalline form of olaparib
|
|
CN112334133A
(zh)
|
2018-02-15 |
2021-02-05 |
生华生物科技股份有限公司 |
喹诺酮类似物及其盐、组合物及其使用方法
|
|
US11542282B2
(en)
*
|
2018-02-28 |
2023-01-03 |
The Trustees Of The University Of Pennsylvania |
Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents
|
|
KR20200130856A
(ko)
|
2018-03-13 |
2020-11-20 |
옹쎄오 |
암 치료에서 획득한 내성에 대한 디베이트 분자
|
|
GB201804924D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Univ Oxford Innovation Ltd |
Radiolabelled compound
|
|
CN110357889B
(zh)
|
2018-04-09 |
2022-03-15 |
上海科技大学 |
蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
|
|
EP3793608A4
(en)
*
|
2018-05-14 |
2022-04-20 |
Nuvation Bio Inc. |
COMPOUNDS TARGETING ANTICANCER NUCLEAR HORMONE RECEPTORS
|
|
CN108558773A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种奥拉帕尼药物中间体的制备方法
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
SG11202111402PA
(en)
|
2019-05-14 |
2021-11-29 |
Nuvation Bio Inc |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
UY38793A
(es)
|
2019-07-19 |
2021-02-26 |
Astrazeneca Ab |
Compuestos químicos
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN115038440A
(zh)
*
|
2020-01-07 |
2022-09-09 |
上海华禹生物科技有限公司 |
使用chk抑制剂的癌症联合疗法
|
|
US20230038138A1
(en)
|
2020-01-09 |
2023-02-09 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
EP4112049A4
(en)
*
|
2020-02-24 |
2024-07-24 |
Fukang (Shanghai) Health Technology Co., Ltd. |
ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR
|
|
CN115702151B
(zh)
|
2020-04-21 |
2025-03-11 |
伊迪恩斯股份有限公司 |
酞嗪酮化合物的结晶形式
|
|
KR20230004724A
(ko)
|
2020-04-21 |
2023-01-06 |
아이디언스 주식회사 |
프탈라지논 유도체 및 이의 중간체의 제조 방법
|
|
FI4143182T3
(fi)
|
2020-04-28 |
2025-03-04 |
Rhizen Pharmaceuticals Ag |
Poly(adp-riboosi)polymeraasin (parp) estäjinä käyttökelpoisia uusia yhdisteitä
|
|
CN111592522B
(zh)
*
|
2020-06-17 |
2022-09-09 |
郑州大学 |
一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
CN116710424A
(zh)
|
2020-09-16 |
2023-09-05 |
努福米克斯技术有限公司 |
奥拉帕利草酸共晶体及其药学用途
|
|
CN116348115A
(zh)
|
2020-10-09 |
2023-06-27 |
阿斯利康(英国)有限公司 |
抗体-药物缀合物和parp1选择性抑制剂的组合
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
WO2022090938A1
(en)
|
2020-10-31 |
2022-05-05 |
Rhizen Pharmaceuticals Ag |
Phthalazinone derivatives useful as parp inhibitors
|
|
CN112500379B
(zh)
*
|
2020-12-23 |
2024-01-23 |
南京方生和医药科技有限公司 |
一种奥拉帕利中间体及奥拉帕利的制备方法
|
|
CN117295747A
(zh)
|
2021-03-23 |
2023-12-26 |
诺维逊生物股份有限公司 |
抗癌核激素受体靶向化合物
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
TW202304447A
(zh)
|
2021-04-08 |
2023-02-01 |
瑞士商瑞森製藥公司 |
聚（ａｄｐ－核糖）聚合酶抑制劑
|
|
JP2024516024A
(ja)
|
2021-05-03 |
2024-04-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
CA3219248A1
(en)
|
2021-05-18 |
2022-11-24 |
Hyun Ju Cha |
Parp inhibitor-resistant cancer therapeutic agent
|
|
IL308684A
(en)
|
2021-06-02 |
2024-01-01 |
Astrazeneca Ab |
Methods of treating breast cancer
|
|
WO2023017393A1
(en)
|
2021-08-09 |
2023-02-16 |
Glenmark Life Sciences Limited |
Process for the preparation of olaparib, and crystalline form thereof
|
|
KR102645122B1
(ko)
*
|
2021-08-25 |
2024-03-07 |
주식회사 보령 |
올라파립의 제조방법
|
|
CN120309514A
(zh)
*
|
2021-09-15 |
2025-07-15 |
上海博邦医药科技有限公司 |
一种奥拉帕尼中间体的制备方法
|
|
US12049452B2
(en)
|
2021-11-10 |
2024-07-30 |
Nuformix Technologies Limited |
Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
|
|
US20250025568A1
(en)
|
2021-11-18 |
2025-01-23 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
AU2022422276B2
(en)
|
2021-12-21 |
2025-12-11 |
Astrazeneca Ab |
Methods of treating brain tumours and neuroblastomas
|
|
KR102776660B1
(ko)
*
|
2022-01-25 |
2025-03-04 |
재단법인 한국파스퇴르연구소 |
벤조다이옥세인 유도체 화합물 및 이의 의약 용도
|
|
EP4479053A1
(en)
|
2022-02-15 |
2024-12-25 |
Astrazeneca AB |
Methods of treating prostate cancer
|
|
AU2023441454A1
(en)
|
2023-03-31 |
2025-11-13 |
Astrazeneca Ab |
Dosing regiment of azd5305
|
|
TW202515604A
(zh)
|
2023-05-31 |
2025-04-16 |
瑞典商阿斯特捷利康公司 |
用於治療卵巢癌之方法、組成物和組合
|
|
AU2024312126A1
(en)
|
2023-06-21 |
2025-12-11 |
Tetragon Biosciences Ltd. |
Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
TW202535479A
(zh)
|
2023-12-05 |
2025-09-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
|
|
WO2025153668A1
(en)
|
2024-01-19 |
2025-07-24 |
Astrazeneca Ab |
Pharmaceutical compositions comprising azd5305
|